Compile Data Set for Download or QSAR
Report error Found 2040 of affinity data for UniProtKB/TrEMBL: P22413
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705284(US20240376113, Compound 85a)
Affinity DataKi:  0.00600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705289(US20240376113, Compound 88a)
Affinity DataKi:  0.00600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705224(US20240376113, Compound 28a)
Affinity DataKi:  0.00800nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705265(US20240376113, Compound 72a)
Affinity DataKi:  0.00900nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705206(US20240376113, Compound 1b)
Affinity DataKi:  0.0150nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705277(US20240376113, Compound 80a)
Affinity DataKi:  0.0160nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705287(3-[(4-{[5-(dimethylamino)-7- methyl-[1,2,4]triazol...)
Affinity DataKi:  0.0180nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705242(US20240376113, Compound 49a)
Affinity DataKi:  0.0240nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705223((4-((5-(dimethylamino)-7-methyl- [1,2,4]triazolo[1...)
Affinity DataKi: <0.0270nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705288((4-{[7-(dimethylamino)-5-methoxy- [1,2,4]triazolo[...)
Affinity DataKi:  0.0270nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705283(5-(dimethylamino)-6-({4- [imino(methyl)oxo-lambda6...)
Affinity DataKi:  0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705249(benzyl(4-((7-(dimethylamino)-5- methyl-[1,2,4]tria...)
Affinity DataKi:  0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705264(3-[(4-{[7-(dimethylamino)-5- methyl-[1,2,4]triazol...)
Affinity DataKi:  0.0290nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705247((4-{[5-cyclopropyl-7- (dimethylamino)-[1,2,4]triaz...)
Affinity DataKi:  0.0350nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705255([cyclopropyl(4-{[7- (dimethylamino)-5-methyl- [1,2...)
Affinity DataKi:  0.0360nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705276(5-(dimethylamino)-6-({4- [imino(methyl)oxo-lambda6...)
Affinity DataKi:  0.0440nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705269(US20240376113, Compound 74a)
Affinity DataKi:  0.0520nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705212(US20240376113, Compound 8a)
Affinity DataKi:  0.0540nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705250((4-{[7-(dimethylamino)-5-methyl- [1,2,4]triazolo[1...)
Affinity DataKi:  0.0600nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705241([4-[{7-[di(2H3)methylamino]-5- methyl-[1,2,4]triaz...)
Affinity DataKi:  0.0620nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705219(US20240376113, Compound 16a)
Affinity DataKi:  0.0630nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705256(N-{2-[(4-{[7-(dimethylamino)-5- methyl-[1,2,4]tria...)
Affinity DataKi:  0.0670nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705211(imino(methyl)(4-((5-methyl-7- (pyrrolidin-1-yl)-[1...)
Affinity DataKi:  0.0720nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705218(imino(methyl)(4-((5-methyl-7- (piperidin-1-yl)-[1,...)
Affinity DataKi:  0.0810nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705252((4-{[7-(dimethylamino)-5-methyl- [1,2,4]triazolo[1...)
Affinity DataKi:  0.0860nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM50638978(CHEMBL5566114)
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of human recombinant ENPP1 expressed in HEK293T cells using cGAMP as substrate at pH 7.5 measured after 3.5 hrs in presence of ATP by lumi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
PubMed
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705281(imino(methyl)(4-{[7-methyl-5- (piperidin-1-yl)imid...)
Affinity DataKi:  0.0980nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733660(US20250115609, Compound 062)
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733657(US20250115609, Compound 054)
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733653(US20250115609, Compound 048)
Affinity DataIC50: 0.100nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705268((4-{[5-chloro-7-(dimethylamino)- [1,2,4]triazolo[1...)
Affinity DataKi:  0.103nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705227(US20240376113, Compound 29a)
Affinity DataKi:  0.106nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705204((4-((7-(dimethylamino)-5-methyl- [1,2,4]triazolo[1...)
Affinity DataKi:  0.109nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705286((4-{[5-(dimethylamino)-7-methyl- [1,2,4]triazolo[1...)
Affinity DataKi:  0.138nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733647(US20250115609, Compound 006)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733645(WO2021061803, Compound 131 | US20250115609, Compou...)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733659(US20250115609, Compound 056)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733658(US20250115609, Compound 055)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733668(US20250115609, Compound 076)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733651(US20250115609, Compound 030)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733667(US20250115609, Compound 074)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733649(US20250115609, Compound 008)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733665(US20250115609, Compound 071)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733648(US20250115609, Compound 007)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM733664(US20250115609, Compound 070)
Affinity DataIC50: 0.150nMAssay Description:ENPP1 was a transmembrane glycoprotein capable of hydrolyzing nucleotides and derivatives with a nucleotide-5′-monophosphate structure. ENPP1 was cap...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/23/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705207(4-((7-(dimethylamino)-5-methyl- [1,2,4]triazolo[1,...)
Affinity DataKi:  0.158nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM50638972(CHEMBL5556000)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of human recombinant ENPP1 expressed in HEK293T cells using cGAMP as substrate at pH 7.5 measured after 3.5 hrs in presence of ATP by lumi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
PubMed
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705251((4-{[7-(dimethylamino)-5-methyl- [1,2,4]triazolo[1...)
Affinity DataKi:  0.165nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705267((2-aminoethyl)(4-{[7- (dimethylamino)-5-methyl- [1...)
Affinity DataKi:  0.167nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 1(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM705254([(4-{[7-(dimethylamino)-5-methyl- [1,2,4]triazolo[...)
Affinity DataKi:  0.190nMAssay Description:Test compounds were plated in a 3× dilution scheme in a 384 well plate. To 50 nL of test compound in DMSO was added 2.5 μL ENPP-1 ECD in Assay Buffer...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Displayed 1 to 50 (of 2040 total ) | Next | Last >>
Jump to: